[Systemic lupus erythematosus. International Conference on Systemic Lupus Erythematosus, Barcelona, March 24-28, 2001].
Mezalek
Z Tazi
ZT
Service de médecine interne, hôpital Ibn Sina, CHU Rabar-Salé, Rabat, Maroc.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000367:Age Factors; D000962:Antimalarials / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D003687:Dehydroepiandrosterone / Q000627:therapeutic use; D005260:Female; D006331:Heart Diseases / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D009369:Neoplasms / Q000209:etiology
D000276:Adjuvants, Immunologic; D000962:Antimalarials; D007166:Immunosuppressive Agents; D003687:Dehydroepiandrosterone; D003520:Cyclophosphamide; D009173:Mycophenolic Acid